Additionally, lenalidomide (LEN) administration enhances SLC44A2 expression primarily through runt-related transcription factor 1 (RUNX1), leading to improvements in aortic aneurysm conditions, which provides a potential new therapeutic strategy for aortic aneurysm. This evidence concerns the gene SLC44A2 and aortic aneurysm.